These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12586109)

  • 1. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening.
    Whitehouse C; Solomon E
    Gynecol Oncol; 2003 Jan; 88(1 Pt 2):S152-7. PubMed ID: 12586109
    [No Abstract]   [Full Text] [Related]  

  • 2. Ovarian cancer screening.
    Alexander-Sefre F; Menon U; Jacobs IJ
    Hosp Med; 2002 Apr; 63(4):210-3. PubMed ID: 11995270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening Cuts Ovarian Cancer Mortality.
    Cancer Discov; 2016 Feb; 6(2):OF1. PubMed ID: 26758578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for familial ovarian cancer: the need for well-designed prospective studies.
    Jacobs I
    J Clin Oncol; 2005 Aug; 23(24):5443-5. PubMed ID: 16110006
    [No Abstract]   [Full Text] [Related]  

  • 5. Personalizing CA125 levels for ovarian cancer screening.
    Dorigo O; Berek JS
    Cancer Prev Res (Phila); 2011 Sep; 4(9):1356-9. PubMed ID: 21893498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
    Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
    Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer: to screen or not to screen.
    Mutch DG
    Obstet Gynecol; 2009 Apr; 113(4):772-774. PubMed ID: 19305318
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of transvaginal ultrasound in screening for ovarian cancer.
    Campbell S; Gentry-Maharaj A
    Climacteric; 2018 Jun; 21(3):221-226. PubMed ID: 29490504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125.
    Tamakoshi K; Kikkawa F; Hasegawa N; Ishikawa H; Mizuno K; Kawai M; Tomoda Y
    Gynecol Obstet Invest; 1995; 39(2):125-9. PubMed ID: 7737582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA-125: a biomarker put to the test.
    Schmidt C
    J Natl Cancer Inst; 2011 Sep; 103(17):1290-1. PubMed ID: 21852262
    [No Abstract]   [Full Text] [Related]  

  • 12. Origin of ovarian cancer may have implications for screening.
    Tuma RS
    J Natl Cancer Inst; 2010 Jan; 102(1):11-3. PubMed ID: 20023201
    [No Abstract]   [Full Text] [Related]  

  • 13. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study.
    Bosse K; Rhiem K; Wappenschmidt B; Hellmich M; Madeja M; Ortmann M; Mallmann P; Schmutzler R
    Gynecol Oncol; 2006 Dec; 103(3):1077-82. PubMed ID: 16904167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
    Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.
    Duffy MJ; Bonfrer JM; Kulpa J; Rustin GJ; Soletormos G; Torre GC; Tuxen MK; Zwirner M
    Int J Gynecol Cancer; 2005; 15(5):679-91. PubMed ID: 16174214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for ovarian cancer: is it worth the risk?
    Bell R
    Nurs Times; 1999 Jan 20-26; 95(3):52-3. PubMed ID: 10076394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is tissue CA125 expression in epithelial ovarian adenocarcinoma heterogenic?
    Sparholt MH; Høgdall CK; Nedergaard L; Heeran MC; Christensen IJ; Høgdall EV
    APMIS; 2013 Jan; 121(1):38-44. PubMed ID: 23030299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor Marker CA125: biochemical and molecular properties].
    Bouanène H; Miled A
    Bull Cancer; 2009 May; 96(5):597-601. PubMed ID: 19435686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening.
    Drescher CW; Nelson J; Peacock S; Andersen MR; McIntosh MW; Urban N
    Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):600-6. PubMed ID: 15066925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevation of tumour marker CA-125 in serum & body fluids: interpret with caution.
    Hussain SF; Camilleri P
    Indian J Med Res; 2007 Jan; 125(1):10-2. PubMed ID: 17332651
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.